Celosia Therapeutics CEO and Director of Commercialisation at Macquarie University, Dr Kathryn Sunn sit down for an interview post the company’s landmark Series A funding announcement, raising $16.75M to support the company’s CTx1000 genetic medicine program targeting ALS disease.
Topics in this interview include:
0:00 Introduction to Dr Sunn
2:20 Dr Sunn on Celosia and taking on the CEO role
3:35 Why was Celosia established
5:15 What is ALS and the current treatment landscape
7:10 The significance of CTx1000, Celosia’s lead program
8:21 Why Celosia has been successful in landing one of the largest Series A raise for a biotech company in Australia
9:35 Use of funds
10:34 Trends and challenges in research commercialisation